Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6905188 | 0.89 | MAPT (0.54) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6903967 | 0.87 | MAPT (0.51) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6899190 | 0.86 | KDM4E (0.52) | MAPTLMNAHTTGAASRC | |
| SCHEMBL7172080 | 0.86 | MAPT (0.50) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6898095 | 0.84 | MAPT (0.56) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6898943 | 0.84 | MAPT (0.55) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6901783 | 0.83 | MAPT (0.52) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6902584 | 0.82 | MAPT (0.60) | MAPTLMNAHTTGAASRC | |
| SCHEMBL6905408 | 0.78 | KDM4E (0.70) | MAPTLMNAGAASMN1; SMN2KMT2A | |
| SCHEMBL6903392 | 0.75 | MAPT (0.56) | MAPTLMNAHTTGAASRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767916-B2 | 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT | INDENA S.P.A. (IT) | 2004-07-27 | — | — | US | claimed |
| EP-1212311-B1 | CHALCONE COUMARINS | INDENA SPA (IT) | 2003-03-26 | — | — | EP | claimed |
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | INDENA S.P.A. (IT) | 2002-10-31 | — | — | US | claimed |
| EP-1212311-A1 | CHALCONE COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | claimed |
| WO-2001017984-A1 | CHALCONE COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | claimed |
| US-6767916-B2 | 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT | INDENA S.P.A. (IT) | 2004-07-27 | — | — | US | disclosed |
| EP-1212311-B1 | CHALCONE COUMARINS | INDENA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | INDENA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
| EP-1212311-A1 | CHALCONE COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017984-A1 | CHALCONE COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | NFKBIA, MKI67, HPD | MAPT 4371/4885LMNA 3048/4885HTT 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.